Clinical trial · Observational
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - TNFi vs Abatacept
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - Tumor Necrosis Factor Inhibitors vs Abatacept
NCT04529902CI-TRIAL-00055189DREAMcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rheumatoid Arthritis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Abatacept | Drug | — | UNRESOLVED |
| Tumor Necrosis Factor Inhibitors | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Tumor necrosis factor inhibitors
- description
- Reference group
- interventionNames
- Drug: Tumor Necrosis Factor Inhibitors
- label
- Abatacept
- description
- Exposure group
- interventionNames
- Drug: Abatacept
Primary outcomes (1)
- measure
- Time to dementia onset
- timeFrame
- Through study completion (a median of 253 days)
- description
- Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Please see https://docs.google.com/spreadsheets/d/11fIivBOto16Gyb\_1xM8AXNHn-EC4v7TiLzCjpbbXF0Q/edit?usp=sharing or Appendix A for full code and algorithm definitions. Medicare timeframe: 2007 to 2017 (end of data availability). Inclusion Criteria: * 1\. No prior use of tumor necrosis factor inhibitors or abatacept anytime prior to cohort entry date * 2\. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date Exclusion Criteria: * 1\. Prior history of dementia measured anytime prior to cohort entry date * 2\. No prior history of rheumatoid arthritis recorded in the 365 days prior to cohort entry date * 3\. Prior history of nursing home admission in the 365 days prior to the cohort entry date
References
Publications (0)
Data not yet available
No reference posted for this study.